TerminatedPhase 2NCT04700280

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

Studying Primary Sjögren disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Galapagos NV
Principal Investigator
Catherine Vincent
Galapagos NV
Intervention
GLPG3970(drug)
Enrollment
31 enrolled
Eligibility
18-74 years · All sexes
Timeline
20212021

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04700280 on ClinicalTrials.gov

Other trials for Primary Sjögren disease

Additional recruiting or active studies for the same condition.

See all trials for Primary Sjögren disease

← Back to all trials